Therapeutic potential of Relaxin-2 in Heart Failure with preserved Ejection Fraction (HFpEF)

CONCLUSIONS: The ZSF1 model showed clear signs of HFpEF, including DD, enlargement of the LA, enhanced hemodynamic stress, increased vulnerability to sustained AF and VF, and elevated glucose and blood pressure. RLX treatment largely reversed DD, hemodynamic stress, and suppressed sustained arrhythmias. RLX elicited cardiac genomic changes, most likely through Wnt/canonical signaling, demonstrating RLX's potential as a therapy for HFpEF.